Samara Rosenfeld

There are several factors, both environmental and familial, that are associated with a higher risk of developing asthma and persistent wheezing.

More studies are needed on the effectiveness and safety of plaque psoriasis therapies for older patients.

The recommendations can help clinicians provide proper treatment to adults suffering acute pain.

More trials must include older patients in order to better understand the safety and efficacy of systemic treatments for atopic dermatitis.

Findings highlight the need for strategies to reduce the high mortality rate among those with hematological malignancies hospitalized with COVID-19.

Low- and moderate-frequency magnetic seizure therapy help patients with treatment-resistant depression go into remission.

The findings suggest the need to possibly revise published food allergy guidelines.

Findings of a new phase 3 trial support the use of secnizadole in patients with trichomoniasis.

Racial disparities exist among patients receiving dialysis.

The findings can lead to an alternative pain option for patients with sickle cell disease.

The study addresses safety concerns related to the risk of keratinocyte carcinoma for patients with atopic dermatitis.

Guideline adoption could lead to more use of thrombolytic therapy.

Additional monitoring is needed among patients receiving opioid therapy.

Tiotropium plus olodaterol is more effective for patients with COPD compared with LABA plus inhaled corticosteroids.

Results of ANDHI provide additional support on the safety and efficacy of benralizumab for patients with asthma.

Dupilumab significantly reduces exacerbation rates in patients with asthma compared to standard of care.

The study paves the way for prospective multi-institutional randomized control trials to further re-enforce the safe use of direct oral anticoagulants in patients with obesity.

Manipulative techniques are not effective for chronic low back pain among relatively young individuals.

Older, white patients and those who use linagliptin are at a higher risk of bullous pemphigoid.

The FDA approved the CBD solution following the results of a randomized, double-blind, placebo-controlled trial.

Being outside is safer than being inside with a lot of people.

Pediatrics is leading the way in prescribing nature.

The FDA will be working over the next few months to ensure tralokinumab is efficient for atopic dermatitis.

An expert explains differences between tralokinumab and other popular agents for atopic dermatitis.

The model can simulate treatment benefit over time with time-varying low-density lipoprotein cholesterol.

Combining the dexamethasone implant with anti-VEGF treatment can restore foveal anatomy in eyes resistant to anti-VEGF injection.

The data from the phase 3 AD Up trial add to existing knowledge of the efficacy and safety of upadacitinib for patients with atopic dermatitis.

Eyes with moderate to severe nonproliferative diabetic retinopathy more often develop eye worsening compared to those with a milder form of the condition.

Patients demonstrate visual gains from baseline but mean visual acuity worsens between 2 and 5 years.

The findings support treating eyes with the condition before they progress to proliferative diabetic retinopathy.